Investment Rating - The industry investment rating is "Positive" (maintained) [2] Core Insights - In January 2026, the heavy truck market showed a strong wholesale performance with approximately 100,000 units sold, while retail sales weakened, expected to decline by 5%-10% year-on-year [5][13] - NIO anticipates an adjusted operating profit of RMB 700 million to RMB 1.2 billion for Q4 2025, marking its first positive quarterly adjusted operating profit [17] - The new energy heavy truck segment experienced a significant decline, with terminal sales expected to drop over 85% month-on-month and the domestic penetration rate falling from 54% in December to around 20% [5][13] Summary by Sections Industry News - The heavy truck market in January 2026 saw a total sales volume of about 100,000 units, a 39% increase compared to the same month last year [13] - The new energy heavy truck segment faced severe declines, with terminal sales expected to drop over 85% month-on-month [5][13] - Tesla is shifting focus to humanoid robots, with plans to release the third-generation Optimus in 2026 and aims for an annual production capacity of 1 million units by 2027 [20] - Xpeng Motors is expected to launch its flagship SUV, the Xpeng GX, in April or May 2026 [14] Market Performance - The A-share automotive sector outperformed the broader market with a weekly increase of 0.47%, ranking 10th among primary industries [24] - The commercial vehicle index rose by 1.34%, led by Jinlong Automobile and Foton Motor [6][29] - The automotive parts sector saw a weekly increase of 0.58%, with Xingmin Zhitong and Yinlun shares leading the gains [6][32] Investment Recommendations - For passenger vehicles, the demand for domestic high-end luxury cars is exceeding expectations, with recommended stocks including JAC Motors and Seres, while Geely is identified as a beneficiary [7] - In the automotive parts sector, companies like Desay SV and Zhejiang Xiantong are recommended due to expected profitability improvements [7]

Investment Rating - The investment rating for the industry is "Positive" (maintained) [2] Core Insights - In January 2026, the heavy truck market showed a strong wholesale performance with approximately 100,000 units sold, marking a significant increase of about 39% compared to the same month last year [5][13] - The terminal sales for heavy trucks are expected to decline by 5% to 10% year-on-year, with a severe drop of over 85% in the new energy truck segment [5][13] - NIO is projected to achieve an adjusted operating profit of 700 million to 1.2 billion RMB in Q4 2025, marking its first positive quarterly adjusted operating profit [17] - The automotive sector is experiencing a shift towards high-end luxury vehicles, with domestic demand exceeding expectations [7] - The automotive parts sector is expected to see an upward turning point in profitability due to industry consolidation and downstream expansion [7] Summary by Sections Industry Key News - In January 2026, the heavy truck market's wholesale sales reached around 100,000 units, with terminal sales expected to decline year-on-year [5][13] - NIO anticipates an adjusted operating profit of 700 million to 1.2 billion RMB for Q4 2025 [17] - BYD plans to localize 50% of its parts manufacturing in Brazil by the end of 2026 [19] - Tesla is transitioning to humanoid robot production, with a long-term business value projected at 25 trillion USD [20] Market Performance - The A-share automotive sector outperformed the broader market with a weekly increase of 0.47%, ranking 10th among major sectors [24] - The commercial vehicle index rose by 1.34%, led by Jinlong Automobile and Foton Motor [6][29] - The automotive parts sector saw a 0.58% increase, with significant gains from companies like Xingmin Zhitong and Yinlun [6][32] Investment Recommendations - For passenger vehicles, high-end domestic brands like JAC Motors and Seres are recommended due to strong demand and favorable competition [7] - In the automotive parts sector, companies such as Desay SV and Zhejiang Xiantong are highlighted for their growth potential [7]

非银金融 2026 年 02 月 08 日 投资评级：看好（维持） 行业走势图 数据来源：聚源 -24% -12% 0% 12% 24% 36% 2025-02 2025-06 2025-10 非银金融 沪深300 相关研究报告 《1 月基金新发显著增长，头部券商业 绩预告符合预期 — 行 业 周 报 》 -2026.2.1 《偏股基金新发同比明显增长，公募 强化基准约束—行业周报》-2026.1.25 《逆周期调节呵护"慢牛"，券商和 保险业务开门红 — 行 业 周 报 》 -2026.1.18 1 月新开户高增超预期，银保渠道实现开门红 ——行业周报 | 高超（分析师） | 卢崑（分析师） | 张恩琦（联系人） | | --- | --- | --- | | gaochao1@kysec.cn | lukun@kysec.cn | zhangenqi@kysec.cn | | 证书编号：S0790520050001 | 证书编号：S0790524040002 | 证书编号：S0790125080012 | |  周观点：1 | 月新开户高增超预期，银保渠道实现开门红 | | 保险在个险和银保两端均实现开 ...

Investment Rating - The investment rating for the coal industry is "Positive" (maintained) [1] Core Viewpoints - The report indicates that coal prices are expected to recover gradually to a reasonable price level of around 750 CNY/ton, influenced by supply constraints and increasing demand due to seasonal factors [3][5] - The report highlights that the price of thermal coal has reached a turning point, with a projected upward trajectory supported by policy adjustments and market dynamics [5][14] - The focus on both cyclical recovery and dividend stability presents a dual investment logic for coal stocks, suggesting that now is an opportune time for investment [6][15] Summary by Sections Investment Logic - Thermal coal prices are expected to rise through a four-step process: repairing central and local long-term contracts, reaching the coal-electricity profit-sharing line, and approaching the breakeven point for power plants, estimated at 860 CNY/ton [5][14] - Coking coal prices are more influenced by supply and demand fundamentals, with target prices based on the ratio of coking coal to thermal coal prices [5][14] Market Performance - The coal index experienced a slight decline of 0.62%, outperforming the CSI 300 index by 0.71 percentage points [8][24] - The average PE ratio for the coal sector is 15.71, and the PB ratio is 1.38, indicating relatively low valuations compared to other sectors [8][9] Key Indicators - As of February 6, the price of Qinhuangdao Q5500 thermal coal was 695 CNY/ton, reflecting a slight increase of 3 CNY/ton from the previous week [3][20] - The price of coking coal at Jingtang Port was reported at 1660 CNY/ton, down from 1800 CNY/ton, indicating a significant weekly decline [20][22] Investment Recommendations - The report suggests a selection of coal stocks based on two main strategies: cyclical recovery and dividend stability, with specific companies highlighted for potential investment [6][15] - Key stocks recommended include: Jin控煤业, 兖矿能源 for cyclical logic; 中国神华, 中煤能源 for dividend potential; 神火股份, 电投能源 for diversified aluminum elasticity; 新集能源, 广汇能源 for growth logic [15][16]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The Chinese innovative pharmaceutical industry is entering a new phase of development characterized by dual breakthroughs in commercialization and internationalization, with significant growth in License-out transactions from $2.562 billion in 2017 to $140.274 billion in 2025 [5][15] - The industry is transitioning from a phase of pipeline expectations to one of performance realization, with over 70% of companies achieving positive revenue growth in 2025 [6][23] - The innovative drug sector has seen a strong performance in early 2026, with the pharmaceutical and biological sector rising by 0.14%, outperforming the CSI 300 index by 1.47 percentage points [7][29] Summary by Sections Section 1: Breakthroughs in Commercialization and Internationalization - The period from 2017 to 2026 is crucial for the recognition of Chinese pharmaceutical companies in the global market, with a notable increase in License-out transactions [5][15] - In early 2026, significant deals were made, including a $12 billion upfront payment from CSPC to AstraZeneca, indicating the growing international competitiveness of Chinese innovative drugs [16][17] Section 2: Performance of the Pharmaceutical Sector - The pharmaceutical sector has shown robust growth, with companies like BeiGene reporting revenues exceeding 36 billion yuan, reflecting strong commercialization capabilities [6][23] - The overall industry is moving towards profitability, with companies like Innovent Biologics and Rongchang Biopharma achieving breakeven for the first time [6][23] Section 3: Market Trends and Subsector Performance - In the first week of February 2026, the Chinese pharmaceutical sector saw a 0.14% increase, with traditional Chinese medicine leading the gains at 2.56% [7][31] - The medical research outsourcing sector also performed well, increasing by 1.99%, while other subsectors like biological products and vaccines experienced declines [7][31][35]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The Chinese innovative pharmaceutical industry is entering a new phase of development characterized by dual breakthroughs in commercialization and internationalization, with significant increases in License-out transaction values from $2.562 billion in 2017 to $140.274 billion in 2025 [5][15] - The industry is transitioning from a phase of pipeline expectations to one of performance realization, with over 70% of companies achieving positive revenue growth in 2025 [6][23] - The innovative drug sector has seen a strong performance in the first week of February 2026, with a 0.14% increase, outperforming the CSI 300 index by 1.47 percentage points [7][29] Summary by Sections Section 1: Breakthroughs in Commercialization and Internationalization - The period from 2017 to 2026 is crucial for the recognition of Chinese pharmaceutical companies in the global market, with a notable increase in License-out transactions [5][15] - In 2026, the upfront payment for License-out transactions has already exceeded 39% of the total for 2025, indicating improved quality and competitiveness of Chinese innovative drug pipelines [5][15][16] Section 2: Performance of the Pharmaceutical Sector - The innovative drug sector is experiencing rapid revenue growth, with companies like BeiGene achieving over 36 billion yuan in revenue, showcasing strong commercialization capabilities [6][23] - Major companies such as Innovent Biologics and Rongchang Biopharma have maintained robust growth due to their core products, with some companies achieving profitability for the first time [6][23][24] Section 3: Market Trends and Subsector Performance - In the first week of February 2026, the traditional Chinese medicine sector saw the highest increase at 2.56%, while other biopharmaceutical sectors experienced declines [7][31] - The medical research outsourcing sector also performed well, with a 1.99% increase, indicating a positive trend in the pharmaceutical industry overall [7][31][35]

2026 年 02 月 08 日 投资评级：看好（维持） 行业走势图 数据来源：聚源 -24% -12% 0% 12% 24% 36% 2025-02 2025-06 2025-10 计算机 沪深300 相关研究报告 《周观点：SpaceX 申请部署百万颗卫 星，剑指太空算力 — 行 业 周 报 》- 2026.2.1 《AWS 和谷歌拉开"云涨价"序幕， 重视 AI 基建产业链 —行业点评报告》 -2026.1.28 《周观点：SpaceX 有望引领太空革命 —行业周报》-2026.1.25 计算机 周观点：2026 年，多模态模型有望迎来 DS 时刻 ——行业周报 刘逍遥（分析师） liuxiaoyao@kysec.cn 证书编号：S0790520090001 市场回顾：本周（2026.2.2-2026.2.6），沪深 300 指数下跌 1.33%，计算机指 数下跌 3.27%。 周观点：2026 年，多模态模型有望迎来 DS 时刻 （1）2026 年，多模态模型有望迎来 DS 时刻 OpenAI 于 2024 年 2 月推出的初代 Sora 模型，堪称视频领域的 GPT‑1 时刻， 2025 年 9 月 ...

Group 1 - The chemical industry is showing clear signs of a cyclical turning point, with policies aimed at reducing excessive competition accelerating supply-demand improvements [3][28] - The basic chemical index has rebounded strongly, closing at 8447 points as of February 6, 2026, representing an increase of approximately 47.9% compared to the beginning of 2025 [3][13] - The chemical product price index (CCPI) reached 4066 points as of February 5, 2026, up about 6.3% from the low of 3825 points on November 5, 2025 [3][14] - The valuation of the chemical industry is recovering but remains at historically low levels, with a price-to-book ratio of 2.60 as of February 6, 2026, up about 20% from 2.17 on December 16, 2025 [3][20] - Capital expenditure in the chemical industry has turned negative since June 2025, indicating the end of the capacity expansion cycle [3][23] Group 2 - The North Exchange has several cyclical-related companies in the chemical new materials sector, including polyurethane, organic silicon, pesticides, PVC, petrochemicals, and soda ash [3][34] - Key companies in the North Exchange include Yinuowei, Jilin Carbon Valley, Jinhua New Materials, Yingtai Biological, Anda Technology, Jiaxian Co., and Deer Chemical, which are essential links in the industry chain [3][34] Group 3 - The North Exchange chemical new materials sector experienced a decline of 3.39% in the week from February 2 to February 6, 2026 [4][36] - The North Exchange 50 index closed at 1520.89 points, with a weekly decline of 0.70% [4][36] - The best-performing stocks in the North Exchange chemical new materials sector for the week included Gebijia (+7.52%), Bingyang Technology (+5.28%), and Yinuowei (+4.23%) [4][42] Group 4 - Recent announcements include the change of control at Kaide Quartz and Bingyang Technology's inclusion in the Sinopec supplier list for acid fracturing materials [5][74]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The report highlights Meituan's acquisition of Dingdong Maicai for approximately $717 million, aiming to enhance its instant retail supply chain efficiency. Dingdong Maicai has achieved profitability for 12 consecutive quarters and operates over 1,000 front warehouses in China, with a monthly purchasing user base exceeding 7 million [4][24][27] - The report emphasizes the importance of supply chain efficiency and product quality in the competitive landscape of the instant retail industry, suggesting that the focus will shift towards these aspects post-acquisition [27] Summary by Sections Industry Dynamics - Meituan's acquisition of Dingdong Maicai is expected to create synergies in supply chain, regional layout, and warehouse scale, enhancing operational efficiency in the East China region [24][27] - Dingdong Maicai's established direct sourcing and self-operated production capabilities are anticipated to be preserved and amplified within Meituan's platform [27] Investment Themes - Investment Theme 1: Focus on high-end and fashionable gold jewelry brands, recommending companies like Laopuhuangjin and Chaohongji, which are expected to benefit from the emotional consumption trend [6][29] - Investment Theme 2: Emphasize retail companies adapting to trends and AI-enabled cross-border e-commerce leaders, with recommendations for Yonghui Supermarket and Aiyingshi [6][29] - Investment Theme 3: Highlight domestic beauty brands that cater to emotional value and innovative safe ingredients, recommending brands like Maogeping and Pola [6][29] - Investment Theme 4: Focus on differentiated medical beauty product manufacturers and leading chain medical beauty institutions, recommending Meilitiantian Medical Health and Aimeike [6][29] Market Performance - The retail and social service indices reported a slight decline of 0.34% and a slight increase of 0.02% respectively during the week of February 2 to February 6, 2026 [14][15] - The brand cosmetics sector showed the highest weekly increase of 4.99%, while the watch and jewelry sector led with a year-to-date increase of 16.56% [16][19] Company Highlights - Laopuhuangjin reported a significant revenue increase of 250.9% in FY2025H1, driven by brand expansion and customer base growth [31][32] - Chaohongji is expected to achieve a net profit growth of 125% to 175% in 2025, supported by differentiated product strength and multi-channel marketing [31][32] - Meilitiantian Medical Health anticipates a net profit increase of at least 34% in 2025, driven by both internal growth and acquisitions [39][40]

Investment Rating - The investment rating for the computer industry is "Positive" (maintained) [1] Core Insights - The report highlights that 2026 is expected to be a pivotal year for multimodal models, which are anticipated to drive growth in the film, gaming, and advertising sectors due to significant improvements in capabilities and reductions in costs [5][12][15] - The launch of the Keling 3.0 series and Byte's Seedance 2.0 models marks a significant advancement in the multimodal field, enabling comprehensive video production processes and enhancing competition among industry players [6][13] - Keling AI has rapidly commercialized its multimodal models, boasting over 60 million creators and generating more than 600 million videos by the end of 2025, with an annual revenue run rate of $240 million [7][14] Summary by Sections Industry Overview - The computer index fell by 3.27% during the week of February 2-6, 2026, while the CSI 300 index decreased by 1.33% [4][16] Multimodal Model Developments - The initial Sora model by OpenAI, launched in February 2024, is compared to a significant breakthrough in video technology, with subsequent models showing substantial advancements [5][12] - The Keling 3.0 series, launched on February 5, 2026, integrates various multimedia capabilities, marking a new era in AI-driven content creation [6][13] Commercialization Potential - The report emphasizes that 2026 will be crucial for the commercialization of multimodal models, driven by enhanced model capabilities and reduced costs, which will lower barriers to entry for users [7][14] Investment Recommendations - Beneficiaries of the anticipated growth in the multimodal sector include companies such as Wanjing Technology, Haitai Ruisheng, and Hongsoft Technology, among others [8][15]